Nociplastic Pain: Difference between revisions
From WikiMSK
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
==Epidemiology== | |||
The prevalence of chronic pain in New Zealand was measured at 16.9% in 2011{{#pmid:21946879|name}} | |||
==Key Articles== | ==Key Articles== | ||
*{{#l:Cohen2016 - nociplastic pain third mechanistic descriptor.pdf}} | *{{#l:Cohen2016 - nociplastic pain third mechanistic descriptor.pdf}} | ||
| Line 5: | Line 8: | ||
*{{#l:Yunus2008 - Central sensitivity syndrome.pdf}} | *{{#l:Yunus2008 - Central sensitivity syndrome.pdf}} | ||
==References== | |||
<references/> | |||
[[Category:Physiology]] | |||
[[Category:Widespread]] | [[Category:Widespread]] | ||
Revision as of 18:10, 27 July 2020
Epidemiology
The prevalence of chronic pain in New Zealand was measured at 16.9% in 2011[1]
Key Articles
- {{#l:Cohen2016 - nociplastic pain third mechanistic descriptor.pdf}}
- {{#l:Woolf2011 - Central sensitisation.pdf}}
- {{#l:Woolf2014 - Nociceptive amplification naming.pdf}}
- {{#l:Yunus2008 - Central sensitivity syndrome.pdf}}
